Curcumin is a popular, plant-derived compound that has been extensively investigated for diverse range of biological activities. Anticancer activity against various types of cancers and high-safety profile associated with curcumin makes it very attractive. In this study, we report the synthesis and evaluation of pyrazole and click chemistry curcumin analogues for Head and Neck cancer. MTT assay against head and neck cancer cell lines CAL27 and UM-SCC-74A revealed the micromolar potency of the synthesized compounds. To determine the possible molecular mechanisms, effect of these analogues in the expression of pSTAT3, pFAK, pERK1/2 and pAKT was studied. Interestingly, compounds 2 and 5 significantly inhibited the pSTAT3 (Tyr 705) phosphorylation. As far as other compounds, they showed potent cytotoxicity against CAL27; however, these compounds did not show any activity on pSTAT3 phosphorylation at IC 50 concentration level. Molecular docking studies revealed the possible binding mode of pyrazole compound 2 in the SH2 domain of STAT3.
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K E Y W O R D S
click chemistry curcumin analogue, curcumin, head and neck squamous cell carcinoma, pyrazole analogue Curcumin, a natural polyphenol which is used as a food colourant, and herbal medicine in Asia. Curcumin has received a lot of attention recently due to its high-safety profile and efficacy in treating various diseases. [1] [2] [3] Potential anticancer activities associated with curcumin make it a promising therapeutic agent. Apart from anticancer activity, it has shown antioxidant, anti-inflammatory, chemopreventive, chemotherapeutic, antimicrobial and antifungal activities. Curcumin ( Figure 1 ) is being vigorously studied for its effect against breast cancer, prostate cancer, liver cancer, ovarian cancer and cervical cancer. [4] It demonstrated cytotoxic effects against cancer cell lines and cytoprotective effects on non-cancer cells. One of the important aspects of curcumin is its high-safety profile of up to 12 g per day oral administration. [5] Nevertheless, there are a number of challenges, low aqueous solubility, poor absorption and rapid metabolism that limits its therapeutic efficacy. [6] Curcumin can exist as a tautomeric mixture of keto and enol forms in solutions, and the enol form was found to be responsible for the rapid degradation of the curcumin. Chakraborti et al., [7] found that the stability of curcumin was improved when the central diketone moiety of the curcumin was replaced by isooxazole and pyrazole groups. Structural modifications of curcumin were proven to be a meaningful approach to discover analogues with enhanced properties. [8] [9] [10] [11] [12] Conjugates of curcumin with β-and γ-cyclodextrin, liposomal and loaded nanoparticles and nanoemulsion are some of the lipid-based colloidal system that has been employed to enhance water solubility and improving its bioavailability. [13] Recent work supports the synergistic effect of curcumin against various cancers when administered with therapeutic cancer agents. Docetaxel, paclitaxel, bicalutamide, phenethyl isothiocyanate, epigallocatechin gallate and other agents in combination with curcumin enhanced cell growth inhibition and apoptosis. [14] Head and neck squamous cell carcinoma (HNSCC) is one of the most common types of cancer in the USA It includes tumours of the mouth, nose, sinuses, salivary gland, throat and lymph nodes in the neck. The oral cavity and pharynx malignancy represent about 4% (34,780) of all cancer cases, with over 9,000 deaths twice as common in men as are women. The potential for recurrence of the malignancy is 35% within 2 years indicating its high importance in treatment. [15] The effect of curcumin to inhibit the expression of matrix metalloproteases (MMP) in HNSCC cells was demonstrated.
CCLL23, CAL27, UM-SCC1 and UM-SCC14A head and neck cancer cells respond differently to curcumin. There is a significant increase in cell death in CCL23 and CAL27 cell lines with 50 μmol/L of curcumin for 24 hr. Treatment of 400 μm of curcumin in a time and concentration manner resulted in nearly 100% cell death. [16] The activity of curcumin against head and neck squamous cell carcinoma in in vitro and in vivo models is reported. [17] Structural modifications of curcumin serve as a meaningful approach to discovering novel analogues to enhance the efficacy and improve its poor pharmacokinetics. A few of the structurally modified curcumin analogous have displayed efficacious antihead and neck cancer activity. [18] Chakravarti et al. reported the over expression of STAT3 in multiple head and neck cancers. [19] Curcumin was found to suppress the IL-6-mediated phosphorylation of STAT3. The growth of immortalized oral mucosal epithelial cells and squamous carcinoma cells was found to be suppressed by curcumin. [20] In the previously published studies, heterocyclic modification at the keto-enol moiety of curcumin has been proven to be an important pharmacophore playing a pivotal role in various biological activities including antioxidant, anti-Alzheimer's, anti-androgenic and cytotoxicity. According to the literature, an appropriate modification at the keto-enol region could cause enhanced potency. [21] In this work, design, synthesis and evaluation of few semisynthetic curcumin analogues for cytotoxic activity against HNSCC cells are reported. Curcumin was isolated from commercial curcumin powder by silica gel column chromatography using CH 2 Cl 2 : MeOH: AcOH. Final product was co-evaporated with toluene to remove traces of acetic acid to obtain pure curcumin 1. Pyrazole analogues, 2, 3, 4, 5 and 6 were prepared (Scheme 1) by treating pure curcumin (1.2 mmol) in glacial acetic acid (9 ml) and substituted hydrazines (2.0 mmol). [22] The solution was refluxed for 8 hr at 118°C and monitored by thin layer chromatography (Dichloromethane: Methanol, 95:5). The solution was evaporated under reduced pressure, coevaporated with toluene. Crude product was further purified by silica gel chromatography, eluting with CH 2 Cl 2 -MeOH. "Click-chemistry" curcumin analogues 8 and 9 were prepared (Scheme 2) by two-step reaction. In the first step monopropargyl, curcumin was prepared using propargyl bromide. The mono-propargyl curcumin was treated with 2,3,4-tri-O -acetyl-β-D-xylopyranosylazide or thioacetate propyl azide, copper sulphate and sodium ascorbate with click chemistry reaction protocol. [23, 24] Details on structural characterization of compounds are provided in the Supporting Information. The in vitro cytotoxicity of the synthesized curcumin analogues (2-9) was evaluated by MTT assay method against head and neck cancer cell lines CAL27 and UM-SCC-74A. [18] Results showed that all the compounds except compound 9 were significantly active ( Figure 2) . To determine the possible molecular mechanisms, a detailed study was done. STAT3 activation in intracellular signalling has been cited as one of the most critical steps in HNSCC progression. Approximately 82% of HNSCC exhibit upregulation of STAT3 expression. However, limited data exist on the role of semisynthetic curcumin analogue on STAT3 pathway in head and neck cancer. To find out the mechanism of the analogues, the effects on pSTAT3, pFAK, pERK1/2 and pAKT signalling were investigated at IC 50 dose level as shown in Figure 3 . Interestingly, Compounds 2 and 5 showed good activity against CAL27 cell line (Figure 2 ), while inhibiting pSTAT3 (Tyr 705) phosphorylation at IC 50 dose level ( Figure 3 ). Moreover 7 showed weak inhibitory activity on pSTAT3 phosphorylation. Compound 8 appears to be acting on pFAK and pAKT pathways. Although compounds 3, 4, 6 and 7, exhibited potent cytotoxicity against CAL27 and UM-SCC-74A (Figure 2 ), but these compounds did not show any activity on pSTAT3, pFAK, PERK1/2 and pAKT signalling pathways. Further studies are needed to support the mechanism of these compounds.
S C H E M E 2 Synthesis of Curcumin click chemistry analogues [Colour figure can be viewed at wileyonlinelibrary.com]

F I G U R E 2
To determine the binding mode, molecular docking of one of the pSTAT3 active compounds, 2 into the SH2 domain of STAT3 was carried out using Fred [25] [26] [27] module.
Omega2 [28, 29] was used to generate conformations of the ligand. The crystal structure of STAT3β (pdb code 1BG1) [30] was used to generate the receptor grid with the help of makereceptor, [25] [26] [27] and a hydrogen bond constraint was applied for Arg609, one of the crucial amino acid in the phosphotyrosine binding pocket.
The predicted binding mode of pyrazole compound 2 showed hydrogen bond formation between the methoxy substituent and Arg609 (Figures 4, 5 ). There is a cation-pi interaction between Lys 591 and the phenyl ring of pyrazole compound. Recent docking studies by Zhang et al. [31] report the interaction of these two residues in the binding of compounds S3I-1757 and S3I-1756. The other phenyl ring has hydrophobic interaction with Pro715.
In conclusion, we synthesized curcumin analogues (compounds 2-9) and tested against head and neck cancer cell lines CAL27 and UM-SCC-74A. Among them, compounds 5 and 8 showed potent cytotoxic activity against HNSCC cell lines. Interestingly, two analogues, 2, 5 have significant effect on pSTAT3 phosphorylation. Interruption of pFAK and pAKT phosphorylation signalling is shown with the compound 8. Compound 5 is the first reported click chemistry curcumin analogue showing good cytotoxic activity. Thus, we investigated the cytotoxic activity of curcumin analogues and studied the possible molecular mechanisms. Moreover, possible binding mode of compound 2 was predicted by docking into the SH2 domain of STAT3. Overall, this study resulted in important findings, and it paves a path to further explore the design and development of more potent compounds for head and neck cancer.
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